Literature DB >> 7807561

Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part I.

C R Thomas1, L V Wood, J G Douglas, K J Stelzer, W Koh, R Panicker.   

Abstract

This two-part article, the last in a series of articles on cancer emergencies, summarizes the common medical emergencies that can occur as a result of infectious processes (Part I) and antitumor treatment secondary to chemotherapy, biological response modifiers, or radiotherapy (Part II). The use of high-dose cytotoxic agents, coupled with the common instillation of indwelling central venous access devices, have altered the spectrum of infectious etiologies that are appreciated in clinical practice. In addition, a myriad of cytotoxic agents and radiotherapeutic treatment schemes are used widely in clinical oncologic practice. While most of their related side effects are not considered life-threatening emergencies, they can be fatal if not recognized early and treated promptly. Moreover, some of these infectious and treatment-related sequelae can be prevented.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7807561      PMCID: PMC2607708     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  41 in total

1.  Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation.

Authors:  J D Meyers; E C Reed; D H Shepp; M Thornquist; P S Dandliker; C A Vicary; N Flournoy; L E Kirk; J H Kersey; E D Thomas
Journal:  N Engl J Med       Date:  1988-01-14       Impact factor: 91.245

2.  Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia.

Authors:  M Rubin; J W Hathorn; D Marshall; J Gress; S M Steinberg; P A Pizzo
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

Review 3.  Manifestations of sepsis.

Authors:  R L Harris; D M Musher; K Bloom; J Gathe; L Rice; B Sugarman; T W Williams; E J Young
Journal:  Arch Intern Med       Date:  1987-11

Review 4.  Supportive care: issues in the use of blood products and treatment of infection.

Authors:  C A Schiffer; J C Wade
Journal:  Semin Oncol       Date:  1987-12       Impact factor: 4.929

Review 5.  Management of fever in patients with cancer and treatment-induced neutropenia.

Authors:  P A Pizzo
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

Review 6.  Management of infection in patients with acute leukemia.

Authors:  J C Wade
Journal:  Hematol Oncol Clin North Am       Date:  1993-02       Impact factor: 3.722

7.  Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group.

Authors:  B E De Pauw; S C Deresinski; R Feld; E F Lane-Allman; J P Donnelly
Journal:  Ann Intern Med       Date:  1994-05-15       Impact factor: 25.391

8.  A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients.

Authors:  B U Mueller; J Skelton; D P Callender; D Marshall; J Gress; D Longo; J Norton; M Rubin; D Venzon; P A Pizzo
Journal:  J Clin Oncol       Date:  1992-12       Impact factor: 44.544

9.  Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials.

Authors:  J Klastersky; S H Zinner; T Calandra; H Gaya; M P Glauser; F Meunier; M Rossi; S C Schimpff; M Tattersall; C Viscoli
Journal:  Eur J Cancer Clin Oncol       Date:  1988

10.  Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.

Authors:  C R Nichols; E P Fox; B J Roth; S D Williams; P J Loehrer; L H Einhorn
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

View more
  1 in total

1.  Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part II.

Authors:  C R Thomas; K J Stelzer; J G Douglas; W J Koh; L V Wood; R Panicker
Journal:  J Natl Med Assoc       Date:  1994-11       Impact factor: 1.798

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.